Chrysanthemum parthenium (L.) Bernh.; Leucanthemum parthenium (L.) Godr. & Gren.; Pyrethrum parthenium (L.) Sm.; and others Asteraceae (Compositae) Altamisa; featherfew; featherfoil Tanaceti parthenii herba Herb The main active constituents are sesquiterpene lactones, mainly parthenolide and its esters, with santamarin, reynosin, artemorin, partholide and chrysanthemonin. Other compounds present are flavonoids such as kaempferol, tanetin and quercetagetin, and volatile oil consisting of α-pinene, bornyl acetate, bornyl angelate, costic acid, camphor and spirotekal ethers (EMA 2010a; Pareek et al. 2011; Williamson et al. 2013). A Cochrane review on the efficacy and safety of feverfew mono-preparations for preventing migraine included five randomised, placebo-controlled, double-blind trials. The authors concluded that there was not enough evidence to support its efficacy in migraine prophylaxis beyond placebo (Pittler and Ernst 2004). Many other clinical studies on feverfew alone or in combination for the treatment of migraines have been conducted, but the EMA has concluded that there is still not enough evidence to support a full product licence based on well-established use and more robust clinical trials assessing larger patient samples are required (EMA 2010b).
Feverfew
Tanacetum parthenium (L.) Sch.Bip.
Synonyms:
Family:
Other common names:
Drug name:
Botanical drug used:
Main chemical compounds:
Clinical evidence:
Migraine prophylaxis:
Rheumatoid arthritis:
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
